Accès ouvert
2026
article
OpenAlex
Nedi̇m Turan, Hacer Yildiz, Sedat Yildirim, Ezgi̇ Turkoglu et autres
The present study aimed to assess whether the baseline pan-immune-inflammation value (PIV), a readily available blood-based marker, is linked to benefits from nivolumab treatment (response and survival) in patients with metastatic non-small cell lung cancer (mNSCLC) receiving second-line or later therapy. The …
tr, ag
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Alper Yaşar, Zeynep Yüksel Yaşar, Sedat Yıldırım, Akif Doğan et autres
Background and Objectives: Positron emission tomography with 18F-FDG (PET-CT) provides a quantitative measure of tumor metabolic activity through the maximum standardized uptake value (SUVmax) of lung tumors—a measure of metabolic activity that may have prognostic value in non-small cell lung cancer (NSCLC). …
tr, ag
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Hüseyin Tepetam, Melike Pekyürek Varan, Omar Alomarı, Sedat Yıldırım et autres
PURPOSE: HER2-targeted therapies (trastuzumab, T-DM1) improve outcomes in HER2-positive breast cancer but are associated with cardiotoxicity. Radiotherapy also carries cardiac risks, although hypofractionated schedules have not shown increased toxicity. This study evaluated the cardiac safety of concomitant HER2-targeted therapies with different radiotherapy …
tr, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Sila Oksuz, Sedat Yildirim, Hacer Şahika Yıldız, Hatice Odabaş et autres
N on-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and continues to be the leading cause of cancer-related deaths worldwide [1].Despite advances in diagnostic and thera-peutic strategies, most patients present with disease at an advanced stage, …
tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Sedat Yildirim, Özlem Nuray Sever, Ezgi Turkoglu, Nisanur Sariyar Busery et autres
Background: Gastric cancer remains one of the most common malignancies and a leading cause of cancer-related mortality worldwide. Human epidermal growth factor receptor 2 (HER2) status is a key biomarker influencing both prognosis and treatment selection. While HER2-positive patients benefit from trastuzumab, …
tr, ag, bh, kh
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Sila Oksuz, Oguzcan Kınıkoglu, Nisanur Sariyar, Mert Ozdemir et autres
BACKGROUND: The use of androgen receptor pathway inhibitors (ARPIs), such as abiraterone and enzalutamide, in combination with androgen deprivation therapy (ADT), has significantly enhanced outcomes in metastatic castration-sensitive prostate cancer (mCSPC). However, validated early prognostic markers to guide treatment decisions are still …
tr
(code pays fourni par la source)
2026
article
OpenAlex
Hatice Odabaş, Omar Alomari, Seval Orman, Nadiye Sever et autres
BACKGROUND: Breast cancer is the leading cause of cancer-related death in women worldwide. Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) represents the most common subtype. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy (ET) constitute standard …
tr, ag, kh
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Sila OKSUZ, Oguzcan Kinikoglu, Uğur Özkerim, Deniz Isik et autres
Background: Antibiotic exposure has been shown to negatively affect immune checkpoint inhibitor (ICI) efficacy in several cancers, possibly by disrupting gut microbiota. It represents a potentially modifiable clinical factor that may influence immunotherapy efficacy in RCC. However, data on renal cell carcinoma …
tr
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Seval Orman, Miray Aydoğan, Nisanur Sarıyar Busery, Sedat Yıldırım et autres
Background: Body mass index (BMI) has been widely investigated as a potential prognostic factor in breast cancer; however, its clinical relevance in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated with CDK4/6 inhibitors remains controversial, particularly …
tr
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Omar Alomari, Ayham Allahaweh, Sondos Alomari, Hatice Odabaş
Background Cognitive dysfunction is a prevalent and debilitating complication among patients with glioma, significantly affecting their independence, treatment adherence, and quality of life (QoL). Aim This meta-analysis aimed to quantify the prevalence, degree, and predictors of cognitive decline in glioma patients and …
tr, ag, jo
(code pays fourni par la source)
Accès ouvert
2026
review
OpenAlex
Beyzanur Güney, Omar Alomari, Elif Nur Arı, Muhammed Edib Mokresh et autres
Background and Aim Whole-brain radiotherapy (WBRT) remains a standard treatment for patients with multiple brain metastases but is associated with substantial cognitive decline, particularly affecting memory and executive functions. Hippocampal avoidance WBRT (HA-WBRT) has emerged as a promising approach to mitigate radiation-induced …
tr, ag, jo
(code pays fourni par la source)
Accès ouvert
2026
conference-paper
OpenAlex
Omar Alomari, Ayham Allahaweh, Muhammed Edib Mokresh, Sondos Alomari et autres
Introduction Seizures are a major cause of morbidity and reduced quality of life (QoL) in patients with glioma, particularly among the elderly. Temozolomide (TMZ), an alkylating agent widely used in glioma therapy, has been hypothesized to exert an additional antiseizure effect by …
tr, ag, jo
(code pays fourni par la source)